Rosacea - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 106 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Rosacea - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Rosacea - Pipeline Review, H2 2014', provides an overview of the Rosacea's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rosacea, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rosacea and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rosacea
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rosacea and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rosacea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rosacea pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rosacea
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rosacea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Rosacea Overview 9
Therapeutics Development 10
Pipeline Products for Rosacea - Overview 10
Pipeline Products for Rosacea - Comparative Analysis 11
Rosacea - Therapeutics under Development by Companies 12
Rosacea - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Rosacea - Products under Development by Companies 17
Rosacea - Companies Involved in Therapeutics Development 18
Allergan, Inc. 18
Valeant Pharmaceuticals International, Inc. 19
Novartis AG 20
Amorepacific Corporation 21
Galderma S.A. 22
Paratek Pharmaceuticals, Inc. 23
Celgene Corporation 24
Paloma Pharmaceuticals, Inc. 25
Foamix Ltd. 26
Gene Signal International SA 27
Cutanea Life Sciences 28
Sol-Gel Technologies Ltd. 29
Signum Biosciences, Inc. 30
Advancell 31
Celtaxsys, Inc. 32
Brickell Biotech, Inc. 33
Delenex Therapeutics AG 34
TWi Pharmaceuticals, Inc. 35
Dermira Inc. 36
Rosacea - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 42
Assessment by Route of Administration 45
Assessment by Molecule Type 47
Drug Profiles 49
oxymetazoline hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ivermectin - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
apremilast - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
omiganan pentahydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
aganirsen - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DRM-02 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
(betamethasone + calcipotriene) - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
DER-45EV - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
PAC-14028 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
PDI-320 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AC-701 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
minocycline - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
sarecycline hydrochloride - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NS2 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
SIG-990 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
DLX-1008 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CTX-4430 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ANs-29 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
minocycline Gel - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GM-1111 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
SIG-989 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SIG-1191 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SIG-1192 - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
P-529 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Rosacea - Recent Pipeline Updates 84
Rosacea - Dormant Projects 95
Rosacea - Discontinued Products 96
Rosacea - Product Development Milestones 97
Featured News & Press Releases 97
Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK 97
Mar 22, 2014: Galderma Announces Positive Results of Phase 3 Trials of Investigational Ivermectin 1% Targeting Papulopustular Rosacea 97
Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission 98
Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea 99
Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso 100
Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33% 100
Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso 101
Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea 102
Feb 27, 2013: Galderma Announces Availability Of Apprilon In Canada For Treatment Of Rosacea 102
Jun 25, 2012: Flower power may be answer to itchy problem 103
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Rosacea, H2 2014 10
Number of Products under Development for Rosacea - Comparative Analysis, H2 2014 11
Number of Products under Development by Companies, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Rosacea - Pipeline by Allergan, Inc., H2 2014 18
Rosacea - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 19
Rosacea - Pipeline by Novartis AG, H2 2014 20
Rosacea - Pipeline by Amorepacific Corporation, H2 2014 21
Rosacea - Pipeline by Galderma S.A., H2 2014 22
Rosacea - Pipeline by Paratek Pharmaceuticals, Inc., H2 2014 23
Rosacea - Pipeline by Celgene Corporation, H2 2014 24
Rosacea - Pipeline by Paloma Pharmaceuticals, Inc., H2 2014 25
Rosacea - Pipeline by Foamix Ltd., H2 2014 26
Rosacea - Pipeline by Gene Signal International SA, H2 2014 27
Rosacea - Pipeline by Cutanea Life Sciences, H2 2014 28
Rosacea - Pipeline by Sol-Gel Technologies Ltd., H2 2014 29
Rosacea - Pipeline by Signum Biosciences, Inc., H2 2014 30
Rosacea - Pipeline by Advancell, H2 2014 31
Rosacea - Pipeline by Celtaxsys, Inc., H2 2014 32
Rosacea - Pipeline by Brickell Biotech, Inc., H2 2014 33
Rosacea - Pipeline by Delenex Therapeutics AG, H2 2014 34
Rosacea - Pipeline by TWi Pharmaceuticals, Inc., H2 2014 35
Rosacea - Pipeline by Dermira Inc., H2 2014 36
Assessment by Monotherapy Products, H2 2014 37
Assessment by Combination Products, H2 2014 38
Number of Products by Stage and Target, H2 2014 41
Number of Products by Stage and Mechanism of Action, H2 2014 44
Number of Products by Stage and Route of Administration, H2 2014 46
Number of Products by Stage and Molecule Type, H2 2014 48
Rosacea Therapeutics - Recent Pipeline Updates, H2 2014 84
Rosacea - Dormant Projects, H2 2014 95
Rosacea - Discontinued Products, H2 2014 96